Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Associations of Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation with Number of Predicted Class II Restricted mHA

Othmane Jadi, BS,BA, Hancong Tang, MS, Junke Wang, MS, Dante Bortone, PhD, Steven Vensko, PhD, Loreall Pooler, Xin Sheng, MS, Christopher A. Haiman, PhD, David Van Den Berg, PhD, Stephen R. Spellman, MS, Marcelo C. Pasquini, MDMS, Theresa E. Hahn, PhD, Paul M. Armistead, MD PhD, Benjamin G. Vincent, MD, Lara E. Sucheston-Campbell, PhDMS

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-142017

Published: 2020

Journal Articles

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Nicholas P. Tschernia, MD, Vaibhav Kumar, MBBS,MS, Dominic T. Moore, MPH, MS, Benjamin G. Vincent, MD, Callie C. Coombs, MD, Hendrik Van Deventer, MD, Matthew C. Foster, MD, Amy E. DeZern, MD, Leo Luznik, MD, Marcie L. Riches, MDMS, Jonathan S. Serody, MD, Ivana Gojo, MD, Joshua F. Zeidner, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-138786

Published: 2020

Journal Articles

Population Distribution of GvL and GvH Minor Histocompatibility Antigens

Kelly Shea Olsen, MSc, Hancong Tang, MS, Junke Wang, MS, Sarah Entwistle, MSc, Dante S. Bortone, PhD, Steven Vensko, PhD, Loreall Pooler, Xin Sheng, MS, Christopher Haiman, David Van Den Berg, PhD, Stephen R. Spellman, MS, Theresa E. Hahn, PhD, Paul M. Armistead, MD PhD, Lara E. Sucheston-Campbell, PhDMS, Benjamin G. Vincent, MD

Blood (2020) 136 (Supplement 1): 23–25.

https://doi.org/10.1182/blood-2020-141120

Published: 2020

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Evidence for Role of Enzymatic Operations in Shared T-Cell Receptors

Mark Woodcock, MD, Adam Buntzman, PhD, Benjamin G. Vincent, MD

Blood (2018) 132 (Supplement 1): 3703.

https://doi.org/10.1182/blood-2018-99-118884

Published: 2018

Journal Articles

Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML

Blood (2018) 132 (Supplement 1): 4054.

https://doi.org/10.1182/blood-2018-99-116608

Published: 2018

Journal Articles

Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Benjamin G. Vincent, MD, Anastasia Ivanova, PhD, Matthew Foster, Catherine C. Coombs, MD, Katarzyna Jamieson, MD, Hendrik Van Deventer, MD, Richard Scibilia, Laura Blanchard, Cassiopeia Frank, Sean Gallagher, Melissa Matson, AGPCNP-BC, Katherine Pepin, Lori Vaught, Nancy Vogler, Ivana Gojo, MD, Leo Luznik, MD, Jonathan S Serody, MD

Blood (2017) 130 (Supplement 1): 1349.

https://doi.org/10.1182/blood.V130.Suppl_1.1349.1349

Published: 2017

Journal Articles

A Dose-Finding Study of Lenalidomide As Post-Remission Therapy for Older Adults with Acute Myeloid Leukemia (AML)

Matthew C. Foster, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Benjamin G. Vincent, MD, Melissa Matson, AGPCNP-BC, Karen McKinnon, PhD, Shannon Reisdorf, BS, Jack Zhang, RN, Will Pulley, BA, Hyman Muss, MD, Anastasia Ivanova, PhD, Joshua F Zeidner, MD

Blood (2017) 130 (Supplement 1): 2631.

https://doi.org/10.1182/blood.V130.Suppl_1.2631.2631

Published: 2017

Journal Articles

Class I HLA Peptide Epitope Binding Efficiency Has No Impact on Graft Vs. Host Disease Incidence Following Allogeneic Hematopoietic Cell Transplantation

Charlotte McIlwaine Story, BS, MD, Jefferson L. Lansford, BS, Dominic T. Moore, MPH, MS, Chang Xu, Benjamin G. Vincent, MD, Paul M. Armistead, MD PhD, Marcie L. Riches, MDMS

Blood (2017) 130 (Supplement 1): 1987.

https://doi.org/10.1182/blood.V130.Suppl_1.1987.1987

Published: 2017

Journal Articles

Bim Regulates the Survival and Suppressive Capability of CD8+ Foxp3+ Regulatory T Cells during Graft Versus Host Disease

Benjamin G. Vincent, MD, Kimberle A. Agle, PhD, Ludovic Belle, PhD, Vivan Zhou, PhD, Clint Piper, BS, Warren D Shlomchik, MD, Jonathan S Serody, MD, William R. Drobyski, MD

Blood (2017) 130 (Supplement 1): 209.

https://doi.org/10.1182/blood.V130.Suppl_1.209.209

Published: 2017

Journal Articles

Identification of Leukemia Associated Minor Histocompatibility Antigens through Computational Prediction and Targeted Mass Spectrometry

Jefferson L. Lansford, BS, Udara Dharmasiri, PhD, Shengjie Chai, BS, Sally A. Hunsucker, PhD, Dante S. Bortone, PhD, James E. Keating, BS, Ian M. Schlup, Gary L. Glish, PhD, Edward J. Collins, PhD, Gheath Alatrash, DO, PhD, Jeffrey J. Molldrem, MD, Paul M. Armistead, MD PhD, Benjamin G. Vincent, MD

Blood (2017) 130 (Supplement 1): 207.

https://doi.org/10.1182/blood.V130.Suppl_1.207.207

Published: 2017

Journal Articles

Mechanism and Activity of ILC2 Cells Post Allo-BMT

Danny W Bruce, PhD, Heather E Stefanski, MD PhD, Benjamin G. Vincent, MD, Trisha Dant, BS, Shannon Reisdorf, BS, Hemamalini Bommiasamy, PhD, David Serody, Justin E Wilson, PhD, Karen McKinnon, PhD, Warren D Shlomchik, MD, Paul M. Armistead, MD PhD, Jenny PY Ting, PhD, John T Woosley, MD PhD, Dietmar MW Zaiss, PhD, Bruce R. Blazar, MD, Andrew NJ McKenzie, PhD, James Coghill, MD, Jonathan S. Serody, MD

Blood (2016) 128 (22): 1155.

https://doi.org/10.1182/blood.V128.22.1155.1155

Published: 2016

Journal Articles

Integrated In Silico Prediction of Minor Histocompatibility Antigen Peptides in HLA-Matched Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Jefferson L. Lansford, Shengjie Chai, Gheath Alatrash, DO, PhD, Jeffrey J. Molldrem, MD, Paul M. Armistead, MD PhD, Benjamin G. Vincent, MD

Blood (2016) 128 (22): 3352.

https://doi.org/10.1182/blood.V128.22.3352.3352

Published: 2016

Journal Articles

Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality

Blood (2015) 126 (23): 147.

https://doi.org/10.1182/blood.V126.23.147.147

Published: 2015

Journal Articles

Role of PD-1/PD-L1 in Acute and Chronic Graft Versus Host Disease

Bruce R. Blazar, MD, Roddy S. O'Connor, PhD, Michael C. Milone, MD PhD, Michael L. Dustin, PhD, James L. Riley, PhD, Benjamin G. Vincent, MD, Jonathan S. Serody, MD, Ryan P Flynn, PhD, Katelyn Paz, Jing Du, Angela Panoskaltsis-Mortari, PhD, Miller Jeffrey, MD, Rafi Ahmed, PhD, Laurence A. A. Turka, MD, Gordon J. Freeman, PhD, Arlene H. Sharpe, MDPhD, Asim Saha, PhD

Blood (2015) 126 (23): SCI-8.

https://doi.org/10.1182/blood.V126.23.SCI-8.SCI-8

Published: 2015

Journal Articles

Effect of Anti-Fungal Prophylaxis on the Fungal Mycobiome after Allogeneic Bone Marrow Transplantation

Shannon Reisdorf, BS, Hemamalini Bommiasamy, PhD, Michelle West, BS, David Serody, Danny Bruce, PhD, Benjamin G. Vincent, MD, James Coghill, MD, Jonathan S. Serody, MD

Blood (2015) 126 (23): 4290.

https://doi.org/10.1182/blood.V126.23.4290.4290

Published: 2015

Journal Articles

UNC-GRK4-1: An Allele Specific Cancer Testis Antigen Identified Through Genomic Screening

Udara Dharamsiri, PhD, Sally A. Hunsucker, PhD, Benjamin G. Vincent, MD, Michael Wu, PhD, Edward J. Collins, PhD, Shoudan Liang, PhD, Jeffrey J. Molldrem, MD, Paul M. Armistead, MD, PhD

Blood (2013) 122 (21): 3246.

https://doi.org/10.1182/blood.V122.21.3246.3246

Published: 2013

Journal Articles

High-Throughput Immunoglobulin Heavy Chain Variable Region Repertoire Analysis Of CD27+ B Cell Subsets From Patients With Chronic Gvhd

Prasanthi V. Tata, MS, Benjamin G. Vincent, MD, Pei-Fen Kuan, PhD, Corbin Jones, PhD, Jonathan Serody, MD, Stefanie Sarantopoulos, MD, PhD

Blood (2013) 122 (21): 2055.

https://doi.org/10.1182/blood.V122.21.2055.2055

Published: 2013

Journal Articles

RNA-Seq Expression Profiling of AML Stem Cells Reveals Differential Expression of Lineage Differentiation Markers and Novel Splice Variants.

Benjamin G Vincent, MD, Darshan Singh, MS, Michael Wu, PhD, Sally A. Hunsucker, PhD, Gheath Alatrash, DO, PhD, Kathryn Ruisaard, MS, Pariya Sukhumalchandra, BS, Karen Clise-Dwyer, PhD, Jonathan S Serody, MD, Jan F Prins, PhD, Jeffrey J. Molldrem, M.D., Paul M. Armistead, MD, PhD

Blood (2012) 120 (21): 2502.

https://doi.org/10.1182/blood.V120.21.2502.2502

Published: 2012

NARROW

Associations of Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation with Number of Predicted Class II Restricted mHA

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Population Distribution of GvL and GvH Minor Histocompatibility Antigens

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Evidence for Role of Enzymatic Operations in Shared T-Cell Receptors

Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML

Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Dose-Finding Study of Lenalidomide As Post-Remission Therapy for Older Adults with Acute Myeloid Leukemia (AML)

Class I HLA Peptide Epitope Binding Efficiency Has No Impact on Graft Vs. Host Disease Incidence Following Allogeneic Hematopoietic Cell Transplantation

Bim Regulates the Survival and Suppressive Capability of CD8+ Foxp3+ Regulatory T Cells during Graft Versus Host Disease

Identification of Leukemia Associated Minor Histocompatibility Antigens through Computational Prediction and Targeted Mass Spectrometry

Mechanism and Activity of ILC2 Cells Post Allo-BMT

Integrated In Silico Prediction of Minor Histocompatibility Antigen Peptides in HLA-Matched Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality

Role of PD-1/PD-L1 in Acute and Chronic Graft Versus Host Disease

Effect of Anti-Fungal Prophylaxis on the Fungal Mycobiome after Allogeneic Bone Marrow Transplantation

UNC-GRK4-1: An Allele Specific Cancer Testis Antigen Identified Through Genomic Screening

High-Throughput Immunoglobulin Heavy Chain Variable Region Repertoire Analysis Of CD27+ B Cell Subsets From Patients With Chronic Gvhd

RNA-Seq Expression Profiling of AML Stem Cells Reveals Differential Expression of Lineage Differentiation Markers and Novel Splice Variants.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only